Systemic Lupus Erythematosus Bulk Plasma
Systemic Lupus Erythematosus Bulk Plasma is collected by apheresis from IRB-consented SLE donors using ACDA anticoagulant and tested negative for HIV, HBV and HCV. High-volume acellular material for anti-dsDNA and ANA autoantibody assays, complement and immune-complex work, interferon-associated biomarker discovery, and plasma proteomics. Stratification by autoantibody profile, disease activity, organ involvement and treatment, with matched healthy controls.
Systemic Lupus Erythematosus Bulk Plasma for Autoimmune Research
Systemic Lupus Erythematosus (SLE) Bulk Plasma is collected by apheresis from IRB-consented donors with a clinically confirmed diagnosis of SLE, using ACDA (Acid-Citrate-Dextrose Formula A) as the anticoagulant. Apheresis yields far more plasma per donor than a standard venipuncture draw, so a single well-characterised lupus donor can support an entire assay-development or biomarker-qualification campaign without introducing donor-to-donor variability. Every lot is tested and confirmed negative for HIV, HBV and HCV, collected under IRB-approved informed consent with HIPAA-compliant data handling, and available fresh or frozen in standard or custom volumes.
Why SLE Plasma for Autoimmune Research
SLE is a systemic autoimmune disease in which loss of tolerance to nuclear self-antigens drives autoantibody production, immune-complex formation and complement-mediated injury across skin, joints, kidney, blood and other organ systems. Much of that cascade is measurable directly in the acellular compartment, which makes high-volume disease-state plasma unusually informative.
- Antinuclear autoantibodies — ANA, anti-dsDNA and anti-Sm/anti-RNP reactivities circulate in plasma and form the serological backbone of lupus classification criteria.
- Immune complexes and complement consumption — circulating nucleic-acid/antibody complexes with reduced C3 and C4 and elevated activation products reflect ongoing complement turnover.
- Type I interferon axis — nucleic-acid-containing immune complexes stimulate plasmacytoid dendritic cells, and the resulting interferon-associated soluble mediator profile is detectable in plasma.
- B-cell survival and inflammatory cytokines — BAFF/BLyS, IL-6, IL-10, TNF-α and interferon-inducible chemokines support B-cell-directed and cytokine-blockade programmes.
- Cell-free nucleic acids and vesicles — apheresis volumes are large enough for cell-free DNA, extracellular-vesicle and neutrophil-extracellular-trap-associated workflows that small aliquots cannot support.
- Correct matrix, by design — plasma is acellular and is the appropriate input for soluble-analyte immunoassays, proteomics and metabolomics; ACDA anticoagulation avoids the coagulation-cascade artefacts introduced when serum is prepared.
Donor Stratification Available
- Autoantibody profile — ANA-positive, anti-dsDNA-positive, anti-Sm/anti-RNP, anti-Ro/anti-La, and antiphospholipid-antibody-positive donors
- Disease activity — donors in active flare versus clinically quiescent or low-activity disease at the time of draw
- Organ involvement — cutaneous, musculoskeletal, haematological, and biopsy-confirmed lupus nephritis donors
- Treatment status — treatment-naive, antimalarial, corticosteroid, conventional immunosuppressant, or biologic-treated donors
- Demographics — age, sex assigned at birth, and race/ethnicity, with cohorts balanced on request
- Matched healthy controls available, drawn on the same protocol and matched for age, sex and ethnicity
Product Features
- High-volume plasma collected via apheresis
- Anticoagulated using ACDA (Acid-Citrate-Dextrose Formula A)
- Tested and confirmed negative for HIV, HBV, and HCV
- Available fresh with custom volumes upon request
- IRB-approved informed consent and HIPAA-compliant handling
- Research Use Only (RUO)
De-identified Donor Data
- Clinically confirmed diagnosis of SLE
- Donor demographics: age, sex assigned at birth, race/ethnicity
- Clinical history and medication data available
- Autoantibody and disease-activity context reported per lot where captured
- Additional SLE-specific clinical fields available on request
Applications
- Anti-dsDNA, ANA and extractable-nuclear-antigen autoantibody assay development and validation
- Complement activation and immune-complex quantification
- Interferon-associated soluble biomarker discovery and signature qualification
- Multiplex cytokine and chemokine profiling across active and quiescent lupus
- Plasma proteomic and metabolomic discovery in systemic autoimmunity
- Cell-free DNA and extracellular-vesicle isolation from large-volume starting material
- Diagnostic and companion-assay reference and calibrator material sourcing
- Target engagement and pharmacodynamic readouts for B-cell- and interferon-directed therapeutics
Other Systemic Lupus Erythematosus Specimen Types
- Systemic Lupus Erythematosus Plasma
- Systemic Lupus Erythematosus Serum
- Systemic Lupus Erythematosus PBMC
- Systemic Lupus Erythematosus Whole Blood
- Systemic Lupus Erythematosus Leukopak
Compliance and Quality Assurance
- Screened negative for HIV, HBV, and HCV
- IRB-approved collection with 21 CFR Part 11-compliant electronic consent
- HIPAA-compliant de-identification of all donor data
- Standardized processing and cryopreservation protocols
Ordering & Customization
Systemic Lupus Erythematosus Bulk Plasma is available in standard or custom volumes. For pricing, documentation or international shipping, please contact learnmore@sanguinebio.com. To compare collection formats or check availability across the wider catalogue, visit our human plasma page.
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Bulk Plasma cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.